European scientific working group on influenza (ESWI)

PharmacoEconomics

Volumn 9, Issue SUPPL. 3, 1996, Pages 1-3

  Palache, A M ^a  

^a ESWI Secretariat   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; EUROPE; INFLUENZA; PHARMACOECONOMICS; PRIORITY JOURNAL;

EID: 0029684430     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199600093-00003     Document Type: Conference Paper

References (19)

1. 1. Stuart-Harris CH, Schild GC. Influenza, the viruses and the disease. London: Edward Arnold Publishers, 1976
2. 2. de Gooyer AC. De Spaanse JB. Tiebosch en Van Lindonk, Amsterdam, 1968
3. 3. RB Couch JA Kasel WP Glezen 1986 Influenza: its control in persons and populations J Infect Dis 153 431 40 3950437 10.1093/infdis/153.3.431 1:STN:280:DyaL287ktF2ksA%3D%3D Couch RB, Kasel JA, Glezen WP, et al. Influenza: its control in persons and populations. J Infect Dis 1986; 153: 431–40
4. 4. World Health Organization. Cell culture as a substrate for the production of influenza vaccines: memorandum from WHO meeting; 1995 Feb; Bull WHO 1995; 73: 431–5
5. 5. KG Nicholson R Snacken AM Palache 1995 Influenza immunization policies in Europe and the United States Vaccine 13 365 9 7793132 10.1016/0264-410X(95)98258-C 1:STN:280:DyaK2MzhtlCitA%3D%3D Nicholson KG, Snacken R, Palache AM. Influenza immunization policies in Europe and the United States. Vaccine 1995; 13: 365–9
6. 6. CB Reimer RS Baker FE Newlin 1966 Influenza virus purification with the zonal ultracentrifuge Science 152 1379 81 5937131 10.1126/science.152.3727.1379 1:STN:280:DyaF287ktFKquw%3D%3D Reimer CB, Baker RS, Newlin FE, et al. Influenza virus purification with the zonal ultracentrifuge. Science 1966; 152: 1379–81
7. 7. Y Ghendon 1990 Vaccination against influenza viruses: current status A Mizrahi Viral vaccines: advances in biotechnologicalprocesses, Vol. 14 Wiley & Sons, Inc New York 159 201 Ghendon Y. Vaccination against influenza viruses: current status. In: Mizrahi A, editor. Viral vaccines: advances in biotechnologicalprocesses, Vol. 14. New York: Wiley & Sons, Inc 1990: 159–201
8. 8. DS Fedson 1996 Evaluating the impact of influenza vaccination Pharmacoeconomics 9Suppl.3 54 61 10.2165/00019053-199600093-00013 Fedson DS. Evaluating the impact of influenza vaccination. PharmacoEconomics 1996; 9 Suppl. 3: 54–61
9. 9. AM Palache 1991 Influenza vaccination: the effect of dose and age on the antibody response A methodological evaluation of serologicalvaccination studies Erasmus University Rotterdam Palache AM. Influenza vaccination: the effect of dose and age on the antibody response. A methodological evaluation of serologicalvaccination studies [PhD Thesis]. Rotterdam: Erasmus University, 1991
10. 10. Public Health Service, USA. Promoting health/preventing disease: objectives for the nation. Washington, DC: US Departmentof Health and Human Services, Public Health Service, 1980: 21–4
11. 11. KG Nicholson MJ Wiselka A May 1987 Influenza vaccination of the elderly: perceptions and policies of general practitioners and outcome of the 1985-86 immunisation programme inTrent, UK Vaccine 5 302 6 3433918 10.1016/0264-410X(87)90156-3 1:STN:280:DyaL1c7ivFSgtg%3D%3D Nicholson KG, Wiselka MJ, May A. Influenza vaccination of the elderly: perceptions and policies of general practitioners and outcome of the 1985-86 immunisation programme inTrent, UK. Vaccine 1987; 5: 302–6
12. 12. WU Hassan AF Henderson NP Keaney 1992 Influenza vaccination in asthma Lancet 339 194 1346060 10.1016/0140-6736(92)90274-7 1:STN:280:DyaK387gs12ktQ%3D%3D Hassan WU, Henderson AF, Keaney NP. Influenza vaccination in asthma [letter]. Lancet 1992; 339: 194
13. 13. AM Palache JW Velden van der 1992 Influenza vaccination in asthma Lancet 339 741 1347604 10.1016/0140-6736(92)90637-I 1:STN:280:DyaK387os1Giuw%3D%3D Palache AM, van der Velden JW. Influenza vaccination in asthma [letter]. Lancet 1992; 339: 741
14. 14. PH Rothbarth BM Kempen MJ Sprenger 1995 Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease Am J Respir Crit Care Med 151 1682 6 7735634 1:STN:280:DyaK2M3ltlGqsg%3D%3D Rothbarth PH, Kempen BM, Sprenger MJ. Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 1682–6
15. 15. DA Foster A Talsma A e el Furumoto-Dawson 1992 Influenza vaccine effectiveness in preventing hospitalisation for pneumoniain the elderly Am J Epidemiol 136 296 307 1415151 1:STN:280:DyaK3s%2FjsFantw%3D%3D Foster DA, Talsma A, Furumoto-Dawson A, et el. Influenza vaccine effectiveness in preventing hospitalisation for pneumoniain the elderly. Am J Epidemiol 1992; 136: 296–307
16. 16. DS Fedson A Wajda JP Nicol 1993 Clinical effectiveness of influenza vaccination in Manitoba JAMA 270 1956 61 8411553 10.1001/jama.1993.03510160074032 1:STN:280:DyaK2c%2FhslSkuw%3D%3D Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956–61
17. 17. KL Nichol KL Margolis J Wuorenma 1994 The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community New Engl J Med 331 778 84 8065407 10.1056/NEJM199409223311206 1:STN:280:DyaK2czksVWqsA%3D%3D Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New Engl J Med 1994; 331: 778–84
18. 18. AS Monto 1996 The clinical efficacy of influenza vaccination Pharmacoeconomics 9Suppl.3 16 22 10.2165/00019053-199600093-00006 Monto AS. The clinical efficacy of influenza vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: 16–22
19. 19. J Perez-Tirse PA Gross 1992 Review of cost-benefit analysis of influenza vaccine Pharmacoeconomics 2 198 206 10147010 10.2165/00019053-199202030-00003 1:STN:280:DyaK2cbgvVajug%3D%3D Perez-Tirse J, Gross PA. Review of cost-benefit analysis of influenza vaccine. Pharmacoeconomics 1992; 2: 198–206